相似文献
1
Proceedings of the seventh annual Women in Melanoma Conference.
Ther Adv Med Oncol. 2025 Jun 14;17:17588359251342039. doi: 10.1177/17588359251342039. eCollection 2025.
2
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference.
Oncoimmunology. 2025 Dec;14(1):2507856. doi: 10.1080/2162402X.2025.2507856. Epub 2025 May 22.
3
From conference to career: Tracing medical pathways of Stanford university's minority medical alliance (SUMMA) premedical conference alumni.
J Natl Med Assoc. 2025 Jun;117(3):208-221. doi: 10.1016/j.jnma.2025.05.001. Epub 2025 May 29.
4
Pelvic floor muscle training with feedback or biofeedback for urinary incontinence in women.
Cochrane Database Syst Rev. 2025 Mar 11;3(3):CD009252. doi: 10.1002/14651858.CD009252.pub2.
5
Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
Br J Dermatol. 2024 Jun 20;191(1):117-124. doi: 10.1093/bjd/ljae053.
6
Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression.
Br J Dermatol. 2024 Jun 20;191(1):24-35. doi: 10.1093/bjd/ljae011.
7
Proceedings of the 17 Annual Conference on the Science of Dissemination and Implementation in Health.
Implement Sci. 2025 Jun 20;20(Suppl 1):29. doi: 10.1186/s13012-025-01433-8.
8
Impact of Immune Checkpoint Inhibitor Therapy on Quality of Life in Patients With Advanced Melanoma: A Systematic Review.
Cancer Nurs. 2023 Nov 16. doi: 10.1097/NCC.0000000000001299.
9
Early diagnosis and delayed treatment of anorectal melanoma in a 19-year-old female: A case report.
Int J Surg Case Rep. 2025 Jul;132:111518. doi: 10.1016/j.ijscr.2025.111518. Epub 2025 Jun 14.
10
Evaluation of an artificial intelligence-based decision support for the detection of cutaneous melanoma in primary care: a prospective real-life clinical trial.
Br J Dermatol. 2024 Jun 20;191(1):125-133. doi: 10.1093/bjd/ljae021.
本文引用的文献
1
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Nat Med. 2023 Nov;29(11):2835-2843. doi: 10.1038/s41591-023-02583-2. Epub 2023 Oct 16.
2
Estimation of the Number of Individuals Living With Metastatic Cancer in the United States.
J Natl Cancer Inst. 2022 Nov 14;114(11):1476-1483. doi: 10.1093/jnci/djac158.
3
Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body.
Soc Sci Med. 2022 May;301:114905. doi: 10.1016/j.socscimed.2022.114905. Epub 2022 Mar 17.
4
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1.
5
Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report.
J Natl Cancer Inst. 2022 Apr 11;114(4):489-495. doi: 10.1093/jnci/djab223.
6
Compassion fatigue among oncologists: the role of grief, sense of failure, and exposure to suffering and death.
Support Care Cancer. 2020 Apr;28(4):2025-2031. doi: 10.1007/s00520-019-05009-3. Epub 2019 Aug 8.
7
Clinical Presentations of Melanoma in African Americans, Hispanics, and Asians.
Dermatol Surg. 2019 Jun;45(6):791-801. doi: 10.1097/DSS.0000000000001759.
8
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
N Engl J Med. 2018 May 10;378(19):1789-1801. doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.
9
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
10
Mucosal melanomas in the racially diverse population of California.
J Am Acad Dermatol. 2017 Feb;76(2):250-257. doi: 10.1016/j.jaad.2016.08.007. Epub 2016 Oct 11.
Zotero 插件